Eupatilin
Catalog No: CFN90190
Eupatilin has anti-inflammatory, and anti-tumor properties, it inhibits the MKN-1 gastric cancer cell proliferation via activation of caspase-3 and the metastatic potential of gastric cancer cells via down-regulation of NF-κB activity followed by reduction of pro-inflammatory cytokine-mediated MMPs expressions. Eupatilin inhibits the signalling of MAPK, IKK, NF-κB and eotaxin-1 in bronchial epithelial cells, leading to inhibition of eosinophil migration. Eupatilin is also a promising therapeutic agent against acute ischemia-induced renal damage, it significantly increases the levels of heat shock protein 70 and B-cell lymphoma protein, and it attenuates inducible nitric oxide synthase, Bcl-2-associated X protein, and caspase-3 levels.
Eupatolide
Catalog No: CFN89045
Eupatolide has anti-inflammatory activity, it inhibits lipopolysaccharide-induced COX-2 and iNOS expression in RAW264.7 cells by inducing proteasomal degradation of TRAF6. It can suppress PDGF-induced proliferation and migration of VSMC through HO-1 induction via ROS-Nrf2 pathway and may be a potential HO-1 inducer for preventing or treating vascular diseases. Eupatolide exhibits potent cytotoxicity against HL-60, SMMC-7721, A-549, MCF-7, and SW-480 cancer cell lines, with IC50 values ranging from 1.57 to 22.58 uM; it sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression, it is a valuable compound to overcome TRAIL resistance in breast cancer cells.
Euphol
Catalog No: CFN89516
Euphol, a novel cannabinoid agonist, it has anti-inflammatory action, it can prevent experimental autoimmune encephalomyelitis in mice, it also prevents inflammatory and neuropathic persistent pain in rodents. Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expression.
